How to resolve AdBlock issue? Emergent BioSolutions Awarded $379.6 Million Procurement Contract
Emergent BioSolutions Inc. has announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. Emergent’s Canadian Subsidiary will serve as the sole subcontractor to deploy RSDL to the U.S. Department of Defense (DoD) through a new contract award to the Canadian Commercial Corporation (CCC). The new contract has a base year, which began in December 2022, and four single year option renewals.
“Emergent has a 25-year history of developing and supplying medical countermeasures (MCM) for the U.S. and other governments around the world,” said Paul Williams, senior vice president, government MCM at Emergent. “RSDL has been a routine part of the U.S. warfighters armamentarium for 13 years. This new contract award demonstrates the unique capabilities of our core MCM business to continue to meet the needs and deliver on the requirements for chemical and biological preparedness of public and military forces, which is an important part of our mission to help protect and enhance life.”
Emergent’s proprietary MCM products and product candidates help to address numerous public health threats, including the RSDL Kit, which is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin. RSDL has been procured for military and first responder use for over a decade and has been deployed in over 30 countries.
“CCC is pleased to act as prime contractor for the purchase of RSDL which is made by Emergent BioSolutions’ Canadian Subsidiary,” said Mr. Bobby Kwon, President and CEO at CCC. “This is once again a testament to the strength of the Canada-U.S. defense relations.”